Karyopharm Therapeutics | KPTI - Current Assets


Karyopharm Therapeutics reported $89.75M in Current Assets for its fiscal quarter ending in September of 2025.





Current Assets Change Date
AbbVie USD 29.06B 523M Dec/2025
Abbott USD 26B 1.16B Dec/2025
Amgen USD 29.06B 1.17B Dec/2025
AstraZeneca USD 28.72B 1.22B Dec/2025
BioCryst Pharmaceuticals USD 355.68M 42.78M Sep/2025
Bristol-Myers Squibb USD 35.63B 2.41B Sep/2025
Eli Lilly USD 55.63B 6.44B Dec/2025
Enanta Pharmaceuticals USD 198.68M 5.65M Dec/2025
GlaxoSmithKline GBP 17.51B 332M Dec/2025
Incyte USD 5.02B 746.01M Dec/2025
J&J USD 55.62B 1.01B Dec/2025
Karyopharm Therapeutics USD 89.75M 8.12M Sep/2025
MacroGenics USD 232.09M 27.15M Sep/2025
Merck USD 47.56B 10.49B Sep/2025
Nektar Therapeutics USD 281.36M 94.79M Sep/2025
Novartis USD 28.2B 2.26B Sep/2025
Novartis USD 28.2B 2.26B Sep/2025
Pfizer USD 46.92B 3.22B Sep/2025
Regeneron Pharmaceuticals USD 18.02B 41.2M Dec/2025
Roche Holding CHF 38.73B 3.03B Dec/2025
Sangamo BioSciences USD 49.89M 12.3M Jun/2025
Takeda JPY 3.12T 195.82B Dec/2025
Tectonic Therapeutic USD 273.24M 17.61M Sep/2025
TG Therapeutics USD 630.76M 31M Dec/2025
Ultragenyx Pharmaceutical USD 643.21M 76.58M Sep/2025
Xencor USD 599.82M 81.38M Dec/2025